Worth reading
38Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Contents of this document
Earnings presentationSecond quarter of the fiscal year ending March 20264 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales2,475,235 thousand yen-24.0%
Operating profit486,486 thousand yen+226.0%
Ordinary income463,257 thousand yen+604.0%
Net income593,868 thousand yen+980.0%
Selling, general and administrative expenses458,757 thousand yen
Full-year earnings forecast
Net Sales¥5,000–5,500 million
Operating profit¥100–500 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Operating profitability is expected to be achieved as originally planned.Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Revenue decrease: fluctuations in market demand for GBS-007 accompanying changes in the competitive environment; operating profit improvement: revised supply prices, switch to products with lower manufacturing costs, lower research and development expenses, and lower other SG&A expenses; increase in interim net income: recording gains on the sale of investment securities as an extraordinary gain
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Exchange rate: ¥160/USDNew initiatives
- Execution of a share subscription agreement to establish the joint venture Alfenax Biologics
- Promoting the development of new biosimilars
- Developing domestic biopharmaceutical manufacturing facilities and launching a CDMO business
- Promoting clinical development in Japan and overseas for the cell therapy business
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | Second quarter of the fiscal year ending March 2026 |
| Net Sales | 2,475,235 thousand yen (YoY -24.0%) |
| Operating profit | 486,486 thousand yen (YoY +226.0%) |
| Ordinary income | 463,257 thousand yen (YoY +604.0%) |
| Net income | 593,868 thousand yen (YoY +980.0%) |
| Selling, general and administrative expenses | 458,757 thousand yen |
| Full-year earnings forecast | Net Sales ¥5,000–5,500 million / Gross profit Not disclosed / Operating profit ¥100–500 million |
| Self-assessment against the plan | Operating profitability is expected to be achieved as originally planned. |
| Breakdown of Factors Affecting the Change | Revenue decrease: fluctuations in market demand for GBS-007 accompanying changes in the competitive environment; operating profit improvement: revised supply prices, switch to products with lower manufacturing costs, lower research and development expenses, and lower other SG&A expenses; increase in interim net income: recording gains on the sale of investment securities as an extraordinary gain |
| Assumptions Underlying the Business Outlook | Exchange rate: ¥160/USD |
| New initiatives | Execution of a share subscription agreement to establish the joint venture Alfenax Biologics, Promoting the development of new biosimilars, Developing domestic biopharmaceutical manufacturing facilities and launching a CDMO business, Promoting clinical development in Japan and overseas for the cell therapy business |
Items this document does not state (19)
Gross profitOperating profit marginResults for the three months of the current quarterProgress against full-year forecastSegment resultsKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company reassessed the changes in the competitive environment and market trends resulting from the market entry of Eylea biosimilars and bio-AG products, as well as the future business outlook for GBS-007. On the profit side, the reasons cited were improved profit margins resulting from revised supply prices and a switch to products with lower manufacturing costs.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.